Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Molecular Diagnostics › AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer

AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer

May 14, 2020
|
Andrea Anderson

NEW YORK – The PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza) appears to extend overall survival when used as a post-chemotherapy maintenance treatment in women with advanced ovarian cancer who carry a BRCA1 or BRCA2 mutation, according to a final survival analysis from the Phase III SOLO2/ENGOT-ov21 trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Featured Webinar

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. 

What's Popular?

In Cancer

  1. Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC

  2. Scorpion Therapeutics Launches With $108 Million in Series A Funding

  3. Early Data in Hand, Verastem Marches Ahead With RAF-MEK Inhibitor Program in KRAS-mutated Cancers

    Premium

  4. SickKids' 'Rigorous' Molecular Analysis IDs Targetable Alterations, Cancer Susceptibility Mutations

    Premium

  5. Maverick Therapeutics to Use Inivata's Liquid Biopsy Assay in Phase I/II Clinical Study

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.